QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Key Points

  • Biotech Pliant Therapeutics gapped up following the company’s announcement of results for a treatment of a lung condition known as idiopathic pulmonary fibrosis. 
  • This marks the second time within a year that Pliant skyrocketed on news about clinical trials for this drug.
  • Five analysts boosted their price target on Pliant since the announcement
  • 5 stocks we like better than Pliant Therapeutics

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Biotech Pliant Therapeutics Inc. (NASDAQ: PLRX) zoomed 34% higher on January 23 and added to that gain in the subsequent session. 

The gap-up followed the company’s announcement of results for a treatment for a lung condition known as idiopathic pulmonary fibrosis. 

Patients with this condition have difficulty breathing due to a buildup of lung scar tissue. They have difficulty breathing due to built-up scar tissue in their lungs. 

The study included a group of patients treated with a 320 mg dose of the company’s bexotegrast drug. The study found that bexotegrast was well tolerated over a 12-week treatment period. 

In the second quarter, Pliant expects to release further data from patients treated for at least 24 weeks. It’s also planning to begin a second phase of clinical trials of bexotegrast in mid-year. 

With the price action on January 23, Pliant gapped out of a cup-with-handle base that began forming in early November. 

The gap-up on January 23 might seem like it puts the stock far out of the buy range, being too extended beyond its cup-with-handle buy point above $24.10. However, a gap higher like that is generally an encouraging sign, indicating that institutions that follow the stock are jumping onboard on optimism about a company-specific development, in this case, the clinical trial results. 

It’s not a case of chasing a stock too far beyond a buy point. However, it would also be normal for Pliant to pull back and digest some gains in the not-so-distant future, as investors who bought at lower levels take profits. 


Gapped Up 159% In July

This marks the second time within a year that Pliant skyrocketed on the news about bexotegrast clinical trials. On July 11, shares gapped an astonishing 159% higher after the company released the results of phase one the trials, which investors liked.

On January 24, shares advanced another 8.78%, closing at $32.94.While that was a pretty strong second-day rally, its possible results were more muted than they may have been otherwise: Pliant announced an offering of $175 million of its common stock

The company said it plans to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and short-term investments, to develop ongoing and future pre-clinical and clinical programs, including bexotegrast and PLN-101095, a treatment for another program. The company cited working capital, operating expenses, and capital expenditures as uses for the new cash influx. 

When a company issues new shares, it often has a negative impact on the share price. That’s because it increases the total number of shares outstanding. Existing investors see their capital diluted; in other words, there are more shares to divide the earnings. 

In Pliant’s case, the stock didn’t decline, likely because investors were still piling in based on optimism about the bexotegrast clinical trial results. 

No Earnings & Meager Revenue

So is this stock buyable? As with any stock, that depends on your risk tolerance and goals. This company is still unprofitable, which is not uncommon in the biotech sector as companies are in the research, development, and clinical trial stages. 

Often, these young biotechs can rise higher based on the promise of a bright future, not so much the current revenue and earnings. In the most recent quarter, Pliant reported revenue of $1.482 million, generated from a development partnership with Novartis AG (NYSE: NVS)

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) and Neurocrine Biosciences, Inc (NASDAQ: NBIX) are examples of small- and mid-cap biotech, respectively, that have managed to rally in recent months despite relatively small earnings, at least relative to larger peers. 

MarketBeat analyst data for Pliant show a consensus rating of “buy” with a price target of $47.11, a 43.02% upside over where the stock is currently trading. Since the January 23 announcement, five analysts boosted their price targets on Pliant, including heavyweights JPMorgan Chase and Citigroup. 

That indicates conviction that the next batches of clinical data will likely result in yet more encouraging results.

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Should you invest $1,000 in Pliant Therapeutics right now?

Before you consider Pliant Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.

While Pliant Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for February 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report
A Guide To High-Short-Interest Stocks Cover

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pliant Therapeutics (PLRX)
2.6155 of 5 stars
$34.87-3.8%N/A-11.90Buy$47.11
Novartis (NVS)
1.9535 of 5 stars
$89.49-0.4%2.41%9.20Hold$85.11
Catalyst Pharmaceuticals (CPRX)
2.9748 of 5 stars
$15.52-2.9%N/A25.44Moderate Buy$20.38
Neurocrine Biosciences (NBIX)
2.444 of 5 stars
$108.25-0.1%N/A189.92Moderate Buy$122.24
Compare These Stocks  Add These Stocks to My Watchlist 

Kate Stalter

About Kate Stalter

Contributing Author: Retirement, Asset Allocation, and Tax Strategies

Kate Stalter is a Series 65-licensed asset manager, with more than two decades of experience in various areas of financial services. As an investment advisor and financial planner, Kate personally manages client portfolios, with a focus on successful retirement, including asset allocation, income generation and tax strategies. Kate also serves as a capital-markets contributor at Forbes.com, and is an expert columnist for the investment advisory channel at U.S. News & World Report.
Contact Kate Stalter via email at stalterkate@gmail.com.

Featured Articles and Offers

Search Headlines: